Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

First Posted Date
2010-01-05
Last Posted Date
2017-07-31
Lead Sponsor
Robert Redner, MD
Target Recruit Count
29
Registration Number
NCT01042704
Locations
🇺🇸

UPMC Cancer Centers - Arnold Palmer at Mountain View, Greensburg, Pennsylvania, United States

🇺🇸

UPMC Cancer Centers - Arnold Palmer at Oakbrook, Greensburg, Pennsylvania, United States

🇺🇸

Hematology/Oncology - Private Practice, McKeesport, Pennsylvania, United States

and more 19 locations

Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately

First Posted Date
2009-11-18
Last Posted Date
2012-01-16
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT01015729
Locations
🇨🇦

Research Site, Scarborough, Ontario, Canada

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage

First Posted Date
2009-11-13
Last Posted Date
2015-12-24
Lead Sponsor
Asan Medical Center
Target Recruit Count
1600
Registration Number
NCT01013532
Locations
🇰🇷

Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of

🇰🇷

Hanyang University Medical Center, Seoul, Korea, Republic of

🇰🇷

Wonju Christian Hospital, Wonju, Gangwon-do, Korea, Republic of

and more 68 locations

Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately

First Posted Date
2009-10-20
Last Posted Date
2010-12-07
Lead Sponsor
AstraZeneca
Target Recruit Count
138
Registration Number
NCT00998075
Locations
🇨🇦

Research Site, Scarborough, Ontario, Canada

TAXUS Libertē Post Approval Study

Completed
Conditions
First Posted Date
2009-10-19
Last Posted Date
2015-08-07
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
4199
Registration Number
NCT00997503
Locations
🇺🇸

Torrance Memorial Medical Center, Torrance, California, United States

🇺🇸

Advanced Cardiac Specialists, Mesa, Arizona, United States

🇺🇸

NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States

and more 79 locations

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

First Posted Date
2009-09-24
Last Posted Date
2019-09-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
107
Registration Number
NCT00983580
Locations
🇺🇸

University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion

First Posted Date
2009-08-14
Last Posted Date
2009-08-14
Lead Sponsor
University of Helsinki
Target Recruit Count
220
Registration Number
NCT00959621
Locations
🇫🇮

Helsinki University Hospital, Helsinki, Finland

Mechanism Based Resistance to Aspirin

First Posted Date
2009-07-30
Last Posted Date
2009-10-15
Lead Sponsor
University of Pennsylvania
Target Recruit Count
400
Registration Number
NCT00948987

Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2009-07-27
Last Posted Date
2011-12-21
Lead Sponsor
University Hospital, Brest
Target Recruit Count
34
Registration Number
NCT00946907
Locations
🇫🇷

CHG Carhaix, Carhaix, France

🇫🇷

HIA Clermont Tonnerre, Brest, France

🇫🇷

CHG Douarnenez, Douarnenez, France

and more 9 locations

Measurement of Platelet Dense Granule Release in Healthy Volunteers

Not Applicable
Withdrawn
Conditions
Interventions
First Posted Date
2009-07-21
Last Posted Date
2015-12-07
Lead Sponsor
Vanderbilt University
Registration Number
NCT00942617
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath